Tumor hypoxia: From basic knowledge to therapeutic implications
Diminished oxygen availability, termed hypoxia, within solid tumors is one of the most
common characteristics of cancer. Hypoxia shapes the landscape of the tumor …
common characteristics of cancer. Hypoxia shapes the landscape of the tumor …
2-Oxoglutarate-dependent dioxygenases in cancer
JA Losman, P Koivunen, WG Kaelin Jr - Nature Reviews Cancer, 2020 - nature.com
Oxoglutarate-dependent dioxygenases (2OGDDs) are a superfamily of enzymes that play
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …
The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting
Y Chen, J Li, L Xu, MA Găman, Z Zou - Cell Death Discovery, 2022 - nature.com
Acute myeloid leukemia (AML) is a hematological malignancy characterized by cytogenetic
and genomic alterations. Up to now, combination chemotherapy remains the standard …
and genomic alterations. Up to now, combination chemotherapy remains the standard …
KDM5 demethylases and their role in cancer cell chemoresistance
J Plch, J Hrabeta, T Eckschlager - International journal of …, 2019 - Wiley Online Library
Histone methylation is important in the regulation of genes expression, and thus its
dysregulation has been observed in various cancers. KDM5 enzymes are capable of …
dysregulation has been observed in various cancers. KDM5 enzymes are capable of …
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma …
L Pommert, ES Schafer, J Malvar… - American journal of …, 2022 - Wiley Online Library
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML)
remain dismal. Epigenetic changes can result in gene expression alterations which are …
remain dismal. Epigenetic changes can result in gene expression alterations which are …
Targeting chromatin-remodeling factors in cancer cells: promising molecules in cancer therapy
FL Zhang, DQ Li - International Journal of Molecular Sciences, 2022 - mdpi.com
ATP-dependent chromatin-remodeling complexes can reorganize and remodel chromatin
and thereby act as important regulator in various cellular processes. Based on considerable …
and thereby act as important regulator in various cellular processes. Based on considerable …
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes
ML Trempenau, MB Schuster, S Pundhir, MA Pereira… - Leukemia, 2023 - nature.com
Epigenetic regulators are frequently mutated in hematological malignancies including acute
myeloid leukemia (AML). Thus, the identification and characterization of novel epigenetic …
myeloid leukemia (AML). Thus, the identification and characterization of novel epigenetic …
[HTML][HTML] Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives
U Chianese, C Papulino, W Megchelenbrink… - Seminars in Cancer …, 2023 - Elsevier
Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and
transcriptional etiology mainly presenting somatic and germline abnormalities. AML …
transcriptional etiology mainly presenting somatic and germline abnormalities. AML …
KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomas
D Wang, Y Zhang, Z Liao, H Ge, C Güngör, Y Li - Scientific Reports, 2023 - nature.com
A growing body of evidence suggests that the histone demethylase-lysine demethylase 5
(KDM5) family is associated with drug resistance in cancer cells. However, it is still not clear …
(KDM5) family is associated with drug resistance in cancer cells. However, it is still not clear …
[HTML][HTML] Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate
AB Das, CC Smith-Díaz, MCM Vissers - Haematologica, 2021 - ncbi.nlm.nih.gov
The past decade has seen a proliferation of drugs that target epigenetic pathways. Many of
these drugs were developed to treat acute myeloid leukemia, a condition in which …
these drugs were developed to treat acute myeloid leukemia, a condition in which …